Abstract
Surgery remains the cornerstone treatment for pancreatic adenocarcinoma. However, 5% to 20% of tumors only are regarded as resectable, and, among them, only few benefit from an histological complete resection, major survival parameter. These data explain the overall poor prognosis of this disease, with a respectively 20% and 5% 1- and 5-year survival rates. These results justify an adjuvant or neoadjuvant therapeutic approach, mainly based on concurrent chemoradiation, with and without surgery. This paper reviews the different therapeutic approaches of non metastatic pancreatic adenocarcinoma.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / mortality
-
Adenocarcinoma / radiotherapy*
-
Adenocarcinoma / surgery
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cisplatin / administration & dosage
-
Cisplatin / therapeutic use
-
Clinical Trials, Phase III as Topic
-
Combined Modality Therapy
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use*
-
Fluorouracil / administration & dosage
-
Fluorouracil / therapeutic use
-
Gemcitabine
-
Humans
-
Neoadjuvant Therapy
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / mortality
-
Pancreatic Neoplasms / radiotherapy*
-
Pancreatic Neoplasms / surgery
-
Radiotherapy Dosage
-
Randomized Controlled Trials as Topic
-
Time Factors
Substances
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Deoxycytidine
-
Cisplatin
-
Fluorouracil
-
Gemcitabine